（原标题：港股异动 | 心通医疗-B(02160)午前涨超4% 将于本月底发布业绩 预期上半年净亏损同比减少 不低于83%） 消息面上，心通医疗-B拟于8月28日举行董事会会议考虑及批准中期业绩。此前，心通医疗-B发布公 告，该集团预期2025年上半年取得净亏损不高于人民币1000万元，同比减少不低于83%。 公告称，净亏损减少主要是由于：VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统已在海外20余个 国家╱地区实现销售，来自海外的收入同比增长两倍以上；AnchorMan左心耳封堵器系统及其导引系统 在中国的商业化进展稳步推进，并于报告期内获得CE标志并在欧洲实现商业化，共同贡献了收入增 量；集团通过持续优化资源配置、积极管控各项费用等措施进一步提升运营效率；及集团的联营公司 4C Medical Technologies, Inc完成D轮融资，集团于4C Medical的股权比例下降，获得视作出售部分股权 的收益。 智通财经APP获悉，心通医疗-B(02160)午前涨超4%，截至发稿，涨4.05%，报1.54港元，成交额1622.65 万港元。 ...

Core Viewpoint - HeartFlow Medical-B (02160) is expected to report a significant reduction in net loss for the first half of 2025, projecting a loss not exceeding RMB 10 million, which represents a year-on-year decrease of no less than 83% [1] Financial Performance - The company anticipates a net loss reduction primarily due to the sales of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system, which has been sold in over 20 countries/regions, resulting in a year-on-year revenue increase of over 200% [1] - The AnchorMan left atrial appendage occluder system and its guiding system have made steady progress in commercialization in China, achieving CE marking and commercializing in Europe during the reporting period, contributing to revenue growth [1] Operational Efficiency - The company has improved operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc. completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

格隆汇8月15日丨心通医疗-B(02160.HK)公告，公司将于2025年8月28日(星期四)举行董事会会议，以考 虑及批准(其中包括)公司及其附属公司截至2025年6月30日止6个月中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 董事會召開日期 微創心通醫療科技有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 本公司將於2025年8月28日（星期四）舉行董事會會議，以考慮及批准（其中包括） 本公司及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈。 承董事會命 微創心通醫療科技有限公司 主席 陳國明 中國上海，2025年8月15日 截至本公告日期，執行董事為張瑞年先生、趙亮先生及閆璐穎女士； 非執行董事為 陳國明先生、張俊傑先生及吳夏女士；及獨立非執行董事為周嘉鴻先生、孫志祥女士及 胡冰山博士。 ...

Core Viewpoint - The company anticipates a significant reduction in net loss for the first half of the year, projecting a loss not exceeding RMB 10 million, which represents a decrease of at least 83% compared to the same period last year [1] Group 1: Financial Performance - The expected net loss for the reporting period is projected to be less than RMB 10 million, marking a reduction of no less than 83% [1] - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty® transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions overseas, resulting in more than a twofold increase in overseas revenue compared to the same period last year [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its delivery system are making steady progress in commercialization in China, having received CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period in 2024 [1] Group 1: Financial Performance - The anticipated net loss reduction is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system in over 20 countries/regions [1] - Revenue from overseas markets has more than doubled compared to the six months ending June 30, 2024 [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its guiding system are making steady progress in commercialization in China [1] - The company obtained CE marking for the AnchorMan® system and has commenced commercialization in Europe during the reporting period [1] Group 3: Operational Efficiency - The company has implemented measures to optimize resource allocation and actively manage expenses, which have further enhanced operational efficiency [1] - The equity stake in the joint venture 4C Medical has decreased following its completion of Series D financing, resulting in recognized gains from the partial sale of shares [1]

本文源自：金融界AI电报 心通医疗-B(02160.HK)公布，该集团预期2025年上半年取得净亏损不高于人民币1000万元，同比减少不 低于83%。 ...

Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period ending June 30, 2024 [1] Group 1 - The significant reduction in net loss is primarily attributed to the sales of the Vita Flow Liberty transcatheter aortic valve and its delivery system in over 20 countries, resulting in more than a twofold increase in overseas revenue compared to the six months ending June 30, 2024 [1] - The commercial progress of the Anchor Man left atrial appendage occluder system and its delivery system in China has been steady, achieving CE marking and commercialization in Europe during the reporting period, contributing to revenue growth [1] - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Core Viewpoint - The company expects to achieve a net loss of no more than RMB 10 million in the first half of 2025, representing a year-on-year reduction of not less than 83% [1] Group 1: Financial Performance - The reduction in net loss is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its delivery system in over 20 countries/regions, with overseas revenue increasing by more than two times year-on-year [1] - The commercial progress of the AnchorMan® left atrial appendage occluder system and its guiding system in China is steadily advancing, having obtained CE marking and commercialized in Europe during the reporting period, contributing to revenue growth [1] Group 2: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which generated income from the sale of part of its equity [1]

微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 股東及潛在投資者於買賣本公司股份時，務請審慎行事。 承董事會命 微創心通醫療科技有限公司 （股份代號：2160） 2025年上半年盈利預告 — 淨虧損大幅減少 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」或「我們」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條以及香港法例第571章證券及期貨條例第XIVA部的內幕消息條文（定義 見上市規則）發出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據 對本集團截至2025年6月30日止六個月（「報告期」）未經審核管理賬目的初步審 閱及對董事會目前可得最新資料的評估，本集團預期報告期錄得淨虧損不高 於人民幣 ...